Fortifying Market Dominance & Driving Pan-African Expansion

Fidson Healthcare Plc, Nigeria’s leading pharmaceutical manufacturer, is pleased to announce the formal launch of its N21 Billion Rights Issue. Following regulatory approval from the Securities and Exchange Commission (SEC) and the Nigerian Exchange Limited (NGX), this strategic capital raise is designed to consolidate our industry leadership and accelerate our growth across the continent.

Why Invest? Exceptional Growth & Market Leadership

Fidson continues to demonstrate robust operational execution and a dominant market position within the West African pharmaceutical landscape. Our performance for the nine-month period ending September 30, 2025, underscores our ability to thrive and create sustainable value:

• Revenue Growth: Reached N93.08 billion, a 56% increase reflecting robust demand and expanded market reach.
• Operating Profit: Rose by 92% to N16.95 billion, driven by effective cost management and operational efficiency.
• Profit After Tax (PAT): Witnessed a significant 132% year-on-year surge, reaching N7.97 billion.
• Proven Track Record: Our growth is reflected in our share value; while our 2019 offering was priced at N4.50, the current offer price of N35.00 represents a testament to our long-term trajectory.

Strategic Use of Proceeds

The N21 billion capital infusion is specifically targeted at key growth pillars to ensure Fidson remains the foremost healthcare company in Nigeria and a dominant player across Africa:

• Increased Manufacturing Capacity: Scaling operations to meet rising regional demand.
• Pan-African Expansion: Driving aggressive market penetration into new territories.
• Product Innovation: Funding the development of new pharmaceutical solutions.
• Technology Upgrades: Optimizing operations through modern infrastructure.